Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical OfficerGlobeNewsWire • 03/13/24
Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver EasierSeeking Alpha • 03/08/24
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating ResultsGlobeNewsWire • 02/28/24
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone PaymentGlobeNewsWire • 02/26/24
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and WebcastGlobeNewsWire • 02/21/24
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late ResearchGlobeNewsWire • 02/20/24
Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences ConferenceGlobeNewsWire • 02/07/24
Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/24
Voyager Therapeutics' Novartis deal has analysts bullish on stock's long-term outlookProactive Investors • 01/02/24
Voyager Therapeutics and Novartis Sign Deal for Neurological Disease TreatmentsInvestopedia • 01/02/24
Novartis Sweetens Its Deal With Voyager, And Voyager Stock — Up 25% — Flashes A Bullish SignInvestors Business Daily • 01/02/24
Voyager Therapeutics shares pop on collaboration with Novartis worth up to $1.2BProactive Investors • 01/02/24
Voyager Therapeutics shares soar 32% on news of deal with Novartis that includes up to $1.2 billion in milestone paymentsMarket Watch • 01/02/24
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene TherapiesGlobeNewsWire • 01/02/24